A Randomized, Open-Label, Single-Dose, Crossover Study to Demonstrate the Bioequivalence of the Final Fixed Dose Combination (FDC) Formulation (COREG CR [carvedilol] and Lisinopril) to COREG CR and ZESTRIL [Lisinopril] Employed in the Phase III Factorial Study

Trial Profile

A Randomized, Open-Label, Single-Dose, Crossover Study to Demonstrate the Bioequivalence of the Final Fixed Dose Combination (FDC) Formulation (COREG CR [carvedilol] and Lisinopril) to COREG CR and ZESTRIL [Lisinopril] Employed in the Phase III Factorial Study

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Oct 2010

At a glance

  • Drugs Carvedilol; Carvedilol/lisinopril; Lisinopril
  • Indications Heart failure; Hypertension
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 12 Jun 2008 Actual patients number 55 added as reported by ClinicalTrials.gov.
    • 12 Jun 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Nov 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top